Conjunctival HLA-DR Expression and Its Association With Symptoms and Signs in the DREAM Study.
HLA-DR
conjunctival cells
correlation
dry eye disease
symptoms and sign
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
22
01
2019
accepted:
20
05
2019
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
9
2019
Statut:
epublish
Résumé
Evaluation of dry eye disease (DED) relies on subjective symptoms and signs. We examined HLA-DR expression (HLA-DR%) in conjunctival cells, a minimally invasive biomarker with objective metrics, as an alternative method. Dry Eye Assessment and Management (DREAM) study participants completed the Ocular Surface Disease Index questionnaire. Clinicians evaluated tear volume, tear breakup time, and corneal and conjunctival staining. Conjunctival impression cytology samples ( The HLA-DR% varied markedly across samples. Over 40% had <5 HLA-DR% positive cells in TCs and ECs and under 23% in WBCs. Higher HLA-DR% was associated with higher conjunctival staining for ECs (mean score 2.77 for <5% and 3.28 for >25%, linear trend The distribution of HLA-DR% in conjunctival cells reflects the heterogeneity of disease in DREAM participants. High percentages of samples with <5% positive cells indicate that HLA-DR% may not be a sensitive marker for DED in all patients. High HLA-DR% in ECs in association with high conjunctival staining may identify a subgroup of DED patients prone to epithelial disease and possibly need a different approach from current standards of treatment.
Identifiants
pubmed: 31489258
doi: 10.1167/tvst.8.4.31
pii: TVST-19-1364
pmc: PMC6707226
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31Subventions
Organisme : NEI NIH HHS
ID : U10 EY022879
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022881
Pays : United States
Références
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2199-212
pubmed: 10476784
Invest Ophthalmol Vis Sci. 2000 May;41(6):1356-63
pubmed: 10798650
Arch Ophthalmol. 2000 May;118(5):615-21
pubmed: 10815152
Ophthalmology. 2000 Oct;107(10):1841-9
pubmed: 11013183
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):90-5
pubmed: 11133852
Hum Immunol. 2001 Jul;62(7):725-31
pubmed: 11423179
NeuroRx. 2004 Apr;1(2):189-95
pubmed: 15717019
Cornea. 2005 Nov;24(8):951-4
pubmed: 16227839
Eye (Lond). 2007 Aug;21(8):1062-6
pubmed: 16710427
Eye Contact Lens. 2007 Jul;33(4):177-9
pubmed: 17630624
Am J Ophthalmol. 2007 Oct;144(4):580-5
pubmed: 17686449
Cornea. 2010 Feb;29(2):167-71
pubmed: 20023577
Exp Eye Res. 2010 Oct;91(4):524-9
pubmed: 20654615
Autoimmun Rev. 2011 Jan;10(3):123-5
pubmed: 20833272
Invest Ophthalmol Vis Sci. 2011 Jul 25;52(8):5488-96
pubmed: 21498621
Acta Ophthalmol. 2011 Nov;89(7):e591-7
pubmed: 21834921
Arch Ophthalmol. 2012 Jan;130(1):90-100
pubmed: 22232476
Ophthalmology. 2012 Jul;119(7):e43-50
pubmed: 22607938
Cornea. 2012 Nov;31(11):1235-9
pubmed: 22677643
Cutan Ocul Toxicol. 2013 Mar;32(1):46-53
pubmed: 22867431
Int J Ophthalmol. 2012;5(4):478-81
pubmed: 22937509
Acta Ophthalmol. 2014 Mar;92(2):161-6
pubmed: 23279964
Exp Eye Res. 2013 Jun;111:95-104
pubmed: 23567204
Br J Ophthalmol. 2014 Sep;98(9):1168-76
pubmed: 24627252
Clin Ophthalmol. 2014 Mar 20;8:581-90
pubmed: 24672224
J Immunol Methods. 2014 Jul;409:54-61
pubmed: 24727143
Rheumatol Int. 2015 Apr;35(4):643-9
pubmed: 25261962
Nat Rev Immunol. 2014 Nov;14(11):719-30
pubmed: 25324123
Eye Contact Lens. 2014 Jul;40(4):248-56
pubmed: 25390549
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
Clin Ophthalmol. 2015 Jun 24;9:1137-45
pubmed: 26170605
Genomics Proteomics Bioinformatics. 2015 Aug;13(4):219-23
pubmed: 26362815
Clin Ophthalmol. 2015 Sep 16;9:1719-30
pubmed: 26396495
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7067-75
pubmed: 26529042
Ocul Surf. 2016 Apr;14(2):264-316
pubmed: 26774910
Sci Rep. 2016 Feb 10;6:20686
pubmed: 26861911
Eur J Ophthalmol. 2016 Jun 10;26(4):287-96
pubmed: 27055414
Ophthalmology. 2016 Jul;123(7):1449-57
pubmed: 27086024
EPMA J. 2016 Jul 13;7:15
pubmed: 27413414
Cent Eur J Immunol. 2016;41(2):195-208
pubmed: 27536206
Autoimmun Rev. 2016 Dec;15(12):1181-1192
pubmed: 27639836
J Ocul Pharmacol Ther. 2017 Jan/Feb;33(1):5-12
pubmed: 27906544
Ophthalmology. 2017 Mar;124(3):280-286
pubmed: 28024826
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2438-2448
pubmed: 28448672
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO1-BIO19
pubmed: 28475698
Ocul Surf. 2017 Jul;15(3):276-283
pubmed: 28736335
Ocul Surf. 2017 Jul;15(3):539-574
pubmed: 28736342
Biomark Med. 2017 Dec;11(12):1135-1147
pubmed: 29182030
N Engl J Med. 2018 May 03;378(18):1681-1690
pubmed: 29652551
Contemp Clin Trials. 2018 Aug;71:70-79
pubmed: 29883769
Int J Mol Sci. 2018 Sep 14;19(9):null
pubmed: 30223431
Mol Clin Oncol. 2018 Oct;9(4):355-361
pubmed: 30233791
J Immunol Methods. 2018 Sep 17;:null
pubmed: 30237053
CLAO J. 1995 Oct;21(4):221-32
pubmed: 8565190
Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1458-64
pubmed: 9191610